Intercept to Present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference
Intercept Pharmaceuticals (Nasdaq: ICPT) has announced that its President and CEO, Mark Pruzanski, will present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference on May 13, 2020, at 2:20 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intercept Pharmaceuticals (Nasdaq: ICPT) has announced that its President and CEO, Mark Pruzanski, will present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference on May 13, 2020, at 2:20 p.m. ET. Investors can access a live webcast on the company’s investor page, with an audio archive available for two weeks post-event. Intercept focuses on developing therapeutics for progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis.
Details
News Market Reaction – ICPT
The recorded move for ICPT in the trading session of this news was +9.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept, will present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference on Wednesday, May 13, 2020 at 2:20 p.m. ET.
A live webcast of the event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An audio archive of the webcast will also be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
CONTACT
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
Source: Intercept Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.